- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 213/40 - Acylated substituent nitrogen atom
Patent holdings for IPC class C07D 213/40
Total number of patents in this class: 589
10-year publication summary
|
52
|
58
|
51
|
41
|
36
|
34
|
35
|
33
|
22
|
0
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| H. Lundbeck A/S | 1247 |
12 |
| The Regents of the University of California | 19479 |
9 |
| Givaudan SA | 1819 |
9 |
| Genentech, Inc. | 3864 |
8 |
| AstraZeneca AB | 2961 |
8 |
| The General Hospital Corporation | 4637 |
8 |
| The Scripps Research Institute | 1353 |
8 |
| Corteva Agriscience LLC | 2677 |
8 |
| Bristol-myers Squibb Company | 4886 |
7 |
| Boehringer Ingelheim International GmbH | 4762 |
7 |
| Amgen Inc. | 3894 |
7 |
| The Broad Institute, Inc. | 1703 |
7 |
| Taisho Pharmaceutical Co., Ltd. | 861 |
7 |
| Massachusetts Institute of Technology | 9903 |
6 |
| Abbvie Inc. | 1781 |
6 |
| Curis, Inc. | 129 |
6 |
| Gilead Sciences, Inc. | 1949 |
6 |
| Glenmark Pharmaceuticals S.A. | 120 |
6 |
| Grünenthal GmbH | 599 |
6 |
| Nippon Soda Co., Ltd. | 884 |
6 |
| Other owners | 442 |